• 1. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 2. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 3. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 4. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 5. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203

Introduction to 4-(Difluoromethoxy)-2-methoxyphenylhydrazine (CAS No. 1804277-51-7)

4-(Difluoromethoxy)-2-methoxyphenylhydrazine, identified by the Chemical Abstracts Service Number (CAS No.) 1804277-51-7, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the phenylhydrazine class, characterized by its phenyl ring substituted with a hydrazine moiety. The presence of both difluoromethoxy and methoxy functional groups on the aromatic ring imparts unique electronic and steric properties, making it a versatile intermediate in the synthesis of biologically active molecules.

The structural features of 4-(Difluoromethoxy)-2-methoxyphenylhydrazine contribute to its potential applications in drug discovery and development. The difluoromethoxy group is known to enhance metabolic stability and binding affinity, while the methoxy group can influence solubility and bioavailability. These properties are particularly valuable in the design of novel therapeutic agents targeting various diseases, including cancer, inflammation, and neurological disorders.

In recent years, there has been a surge in research focused on developing small-molecule inhibitors that modulate enzyme activity and signal transduction pathways. 4-(Difluoromethoxy)-2-methoxyphenylhydrazine has emerged as a key building block in the synthesis of such inhibitors. Its ability to undergo selective reactions with carbonyl compounds via condensation reactions makes it an excellent precursor for constructing heterocyclic scaffolds. These scaffolds are often found in bioactive molecules with potent pharmacological effects.

One of the most compelling aspects of 4-(Difluoromethoxy)-2-methoxyphenylhydrazine is its role in the development of kinase inhibitors. Kinases are enzymes that play a crucial role in cell signaling pathways, and their dysregulation is associated with numerous diseases, particularly cancer. By incorporating the difluoromethoxy and methoxy groups into kinase inhibitors, researchers can fine-tune binding interactions with target proteins, leading to improved efficacy and reduced side effects. Several preclinical studies have demonstrated the potential of phenylhydrazine derivatives as kinase inhibitors, highlighting the importance of compounds like 4-(Difluoromethoxy)-2-methoxyphenylhydrazine.

The synthesis of 4-(Difluoromethoxy)-2-methoxyphenylhydrazine involves multi-step organic transformations that require precise control over reaction conditions. The introduction of the hydrazine group typically involves nucleophilic aromatic substitution or reductive amination, depending on the starting material. The subsequent functionalization with difluoromethoxy and methoxy groups often employs palladium-catalyzed cross-coupling reactions or direct fluorination techniques. These synthetic strategies ensure high yields and purity, which are essential for pharmaceutical applications.

From a medicinal chemistry perspective, 4-(Difluoromethoxy)-2-methoxyphenylhydrazine serves as a valuable scaffold for structure-activity relationship (SAR) studies. By systematically varying substituents on the phenyl ring, researchers can elucidate key structural features that influence biological activity. This approach has led to the discovery of several lead compounds with promising therapeutic profiles. The compound's versatility also allows for modifications that enhance pharmacokinetic properties, such as oral bioavailability and tissue distribution.

The growing interest in fluorinated compounds has further underscored the significance of 4-(Difluoromethoxy)-2-methoxyphenylhydrazine. Fluoro substituents are widely recognized for their ability to improve drug-like properties, including lipophilicity, metabolic stability, and binding affinity. The incorporation of fluorine atoms into drug candidates has been associated with enhanced therapeutic efficacy across a range of indications. As a result, compounds like 4-(Difluoromethoxy)-2-methoxyphenylhydrazine are being extensively explored in academic and industrial research settings.

In conclusion, 4-(Difluoromethoxy)-2-methoxyphenylhydrazine (CAS No. 1804277-51-7) is a multifaceted compound with significant potential in pharmaceutical research and drug development. Its unique structural features make it an ideal candidate for synthesizing biologically active molecules targeting various diseases. The ongoing research into its applications in kinase inhibition and other therapeutic areas underscores its importance in modern medicinal chemistry. As our understanding of molecular interactions continues to evolve, compounds like this will play an increasingly critical role in shaping the future of medicine.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)